Adaptive treatment using neratinib shows benefit in early breast cancer
1. The addition of neratinib to standard therapy was more likely to result in higher pathological complete response rates compared...
Adaptive treatment using veliparib-carboplatin shows benefit in breast cancer
1. The addition of veliparib-carboplatin to standard therapy in treating triple-negative breast cancer patients showed higher rates of pathological complete...
PD-1 blocker pembrolizumab may be a promising therapy for advanced Merkel-cell carcinoma
1. Using immune checkpoint blockade, this phase 2 study showed favourable complete and partial response rates, and increased progression free...
Adaptive interim PET-CT guides treatment for advanced Hodgkin’s lymphoma
1. The use of interim PET-CT scanning can de-escalate chemotherapy use during treatment for advanced Hodgkin’s disease by using doxorubicin,...
Triple therapy prolongs progression-free survival in Multiple Myeloma
1. Adding the proteasome inhibitor Ixazomib to lenalidomide and dexamethasone significantly increased progression-free survival compared to lenalidomide and dexamethasone...
Radiation plus chemotherapy confers survival benefit compared to radiation alone in low-grade gliomas
1. In grade 2 glioma patients younger than 40 years old that have undergone subtotal tumour resection, or in patients...
No difference in PET-CT surveillance versus planned neck dissection in advanced head and neck cancer
1. The overall survival rate for advanced head and neck (H&N) cancer patients undergoing PET-CT guided surveillance was similar to...
Weekly Paclitaxel does not prolong progression-free survival in ovarian cancer
1. A weekly dosing regimen of Paclitaxel versus the standard dosing of Paclitaxel every 3 weeks, both administered with...
CDX2 a promising prognostic biomarker in Stage II/III colon cancer
1. The expression status of biomarker CDX2 was identified as an independent prognosticator in stage II and III colon...
Hodgkin’s Lymphoma survivors at risk for secondary malignancy 40 years post treatment
1. The risk of a second solid cancer following treatment for Hodgkin’s Lymphoma (HL) did not change significantly between...
